1.Date of occurrence of the event:2022/02/21

2.Company name:Microbio (Shanghai) Co., Ltd.

3.Relationship to the Company (please enter ”head office” or

”subsidiaries”):subsidiary

4.Reciprocal shareholding ratios:NA

5.Cause of occurrence:

SNS812 is a siRNA new drug targeting a highly conserved region of

SARS-CoV-2. Unlike traditional antiviral agents, such as nucleoside analog

(eg. molnupiravir) or proteinase inhibitor (eg. paxlovid) which inhibits the

virus by interrupting replication or interfering protein maturation, SNS812

directly and specifically cleaves and destroys the viral RNA by a special

mechanism called RNA interference. The analysis indicates that SNS812 is

capable to cover 99.8% of SARS-CoV-2 variants and has the highest coverage

SNS812 can inhibit original

(A.3),α(Alpha)、β(Beta)、γ(Gamma)、ε(Epsilon) and δ(Delta) strains

with pM range of IC50 in vitro, and effectively prevent or treat SARS-CoV-2

infection in hACE2 transgenic mice. Furthermore, SNS812 is highly specific

to the virus, which represents non-immunogenicity and safety in animal

toxicity studies and thus potentially reduce treatment risk and side effects

compared with other small-molecule drugs.

The research article has been accepted by EMBO Molecular Medicine and

published on 2022/02/21.

6.Countermeasures:None

7.Any other matters that need to be specified:

(1) European Molecular Biology Organization (EMBO) is a professional

organization with strong influence to promote research in life science

and enable international communication between scientists. EMBO has been

well-known for its rigorous review and high quality of publication. EMBO

Molecular Medicine has the highest impact factor (IF: 12.137) among EMBO

series of journals. Moreover, EMBO Molecular Medicine is ranked the 7th

of 140 journals in the category of Medicine, Research and Experimental

and top 5% of all journals. The article of SNS812 can be accessed:

https://www.embopress.org/doi/full/10.15252/emmm.202115298.

(2) The publication of the study results of SNS812 in EMBO Molecular

Medicine represents the acknowledgement by the top international journal

not only on the research and development of siRNA drug, but also on the

scientific evidence and therapeutic potential of SNS812 for the

treatment of COVID-19。

(3) The trend of SARS-CoV-2 infection is gradually becoming flu-like, so the

development of therapeutic drugs is critically needed. SNS812 is a

broad-spectrum siRNA with both therapeutic and preventive efficacy

against a wide range of variants of SARS-CoV-2. The goal is to develop

a pan-COVID-19 therapeutic for the pandemic.

(4) SNS812 is currently under cGMP product with the CMO followed by

toxicology studies with the CRO. It has been planned to submit the IND

application to the US FDA in the middle of 2022.

(5) The development of new drugs is with great risks. The promising data in

animal　studies do not guarantee the clinical success.